Zoetis (ZTS) shares fell 3% on November 6, 2026, to $79.63, after the company’s cautious 2027 outlook offset better-than-expected third-quarter results and a raised 2026 forecast. The stock had rallied 11% over the past month, but the post-earnings drop has pushed it back below the $80 round number, where sellers have repeatedly appeared. With the weekly trend still down and the rally now stalling, the balance of evidence leans neutral for the next 2–6 weeks, with low conviction.
Why it matters
Zoetis reported third-quarter adjusted earnings of $1.75 per share, beating the consensus of $1.51, and sales of $2.391 billion also exceeded expectations despite a 1% revenue decline, according to Benzinga. The company raised its 2026 adjusted earnings forecast, but shares fell over 7% on November 5 after management issued a cautious outlook for 2027, citing rising veterinary costs and intensifying competition in the companion-animal business, as reported by Reuters. The market’s reaction suggests that the better-than-expected quarter was already priced in, and the forward-looking caution dominated.
The 5-day move in ZTS was essentially flat (-0.1%), while the S&P 500 fell 2.7% and the healthcare sector ETF XLV dropped 1.8%. The stock outperformed its sector by 1.6 percentage points over that period, indicating that the post-earnings decline was partly offset by relative strength. Over the past month, ZTS is up 11.3%, while XLV is up 7.6% and the S&P 500 is down 5.3%, showing that the stock has been leading the market on a bounce, but that leadership is now being tested.
The debate among analysts is split. On the bearish side, Seeking Alpha argues that weakening demand for pet healthcare, price-sensitive consumers, and competition overshadow the stock’s discounted valuation, noting that management cut 2026 EPS guidance earlier. On the bullish side, articles on Yahoo! Finance and The Motley Fool highlight ZTS as a cheap dividend stock, trading at a trailing P/E of about 13x versus its five-year average of 27x. The consensus analyst target is $88.38, about 10% above the current price, with a low of $74 and a high of $115, reflecting wide disagreement about the company’s prospects.
What the evidence says
The long-term trend remains down: ZTS trades below its 40-week average, and the stock is down 39% from its 52-week high of $131.10. The thesis is weakened but not broken — the company is still profitable and beating estimates, but the cautious 2027 outlook suggests that the fundamental headwinds are not abating. The stock is in a corrective phase within a downtrend, having bounced from the low of $69.10 but failing to reclaim the 200-day average at $92.50.
For the next 2–6 weeks, the balance of evidence leans neutral. The rally against the weekly downtrend is not yet stretched — the RSI is at 50, right in the middle — and the stock has led the S&P 500 by 8.7% over the past 50 days, but it lags XLV by 1.0% over the same period. Conviction is low, with only 1 of 4 conviction points in favor. The strongest case against a neutral reading is that the stock has already dropped 10.7% from its November 4 peak of $89.20, and the post-earnings breakdown below $80 could signal that the bounce is over. However, the stock is still above its 50-day average at $75.70, and the relative strength versus the market suggests that buyers are not entirely absent. That is why conviction is low rather than negative.
Levels that matter
The structure holds below $80.00, a round number where sellers have shown up on rallies. The weekly trend is down, and as long as ZTS stays below $80, the path of least resistance is lower. The trend would end on a weekly close above $92.50, the 200-day average, which is also a round number and a major resistance level.
The breakout level to the downside is a daily close below $78.20, a swing zone. From there, the first target is the 50-day average at $75.70, giving a reward-to-risk of 1.0 against a stop at $80.68 (based on $80.00 plus a quarter of the ATR). The second target is $73.47, another swing zone, with a reward-to-risk of 1.9. Neither reaches the 3-to-1 threshold that would make a breakdown worth the risk. To get to 3-to-1, the stock would need to fall to around $71.50, which is near the next support at $71.24.
What would change the picture
A weekly close above $92.50 would flip the long-term trend from down to up, as that is the 200-day average and a level that has capped rallies for months. On the fundamental side, a clear sign that the companion-animal business is stabilizing — such as a halt in the decline in U.S. vet visits or a reversal in the 8% drop in companion animal sales — would change the narrative. Until then, the cautious outlook will likely keep a lid on the stock.
What to watch
- Next earnings: already reported on November 5, 2026; the key number is the 2027 guidance, specifically any commentary on U.S. vet visit trends and pricing power.
- Sector events: any news on pet insurance penetration or veterinary cost inflation, as these directly affect demand for ZTS products.
- Valuation: the stock trades 9.9% below the mean analyst target of $88.38, but the low target of $74 suggests that some analysts see further downside if the pet economy weakens.